Literature DB >> 11473682

Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up.

R Schwertz1, U Rother, D Anders, N Gretz, K Schärer, M Kirschfink.   

Abstract

Fifty children with idiopathic membranoproliferative glomerulonephritis (MPGN), aged 2-14 years at apparent onset, were monitored for the presence of C3 nephritic factor (C3 NeF) and signs of complement activation in serum. In addition, C3 allotyping was performed in 32 patients. Observation time ranged from 2 to 20 (median 11) years. C3 NeF activity was detected at least once in 60% of the patients (in 11 of 26 with type I, in 15 of 17 with type II, and in four of seven with type III). C3 NeF-positive patients had significantly reduced levels of CH50 and C3 and elevated levels of C3dg/C3d. During follow-up, C3 levels were persistently normal in 62% of the patients with MPGN type I and in 43% with type III but in only 18% with type II. C3 allotype frequencies differed from those found in healthy controls with a significant shift to the C3F/C3FS variants in C3 NeF-positive patients. C3b(Bb)P as a marker for alternative pathway activation was not increased in C3 NeF-positive patients. Despite the presence of C3 NeF activity, C3 levels remained normal in six patients throughout the observation period. C3 NeF became undetectable in six patients, whereas seven developed C3 NeF activity during follow-up. There was no significant difference in renal survival probability in patients with or without C3 NeF activity. Neither C3 variants nor continuous low C3 or low CH50 levels had any prognostic value for the clinical outcome. No factor H deficiency was detected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473682     DOI: 10.1034/j.1399-3038.2001.012003166.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  39 in total

1.  A case of regression of atypical dense deposit disease without C3 deposition in a child.

Authors:  Min Sun Kim; Pyoung Han Hwang; Mung Jae Kang; Dae-Yeol Lee
Journal:  Korean J Pediatr       Date:  2010-07-31

2.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

Review 3.  Factor I and factor H deficiency in renal diseases: similar defects in the fluid phase have a different outcome at the surface of the glomerular basement membrane.

Authors:  Peter F Zipfel; Richard J H Smith; Christine Skerka
Journal:  Nephrol Dial Transplant       Date:  2008-12-04       Impact factor: 5.992

4.  Regulated secretion of complement factor H by RPE and its role in RPE migration.

Authors:  Yeong Hoon Kim; Shikun He; Satoru Kase; Mizuki Kitamura; Stephen J Ryan; David R Hinton
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-13       Impact factor: 3.117

Review 5.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

6.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).

Authors:  M A Abrera-Abeleda; C Nishimura; J L H Smith; S Sethi; J L McRae; B F Murphy; G Silvestri; C Skerka; M Józsi; P F Zipfel; G S Hageman; R J H Smith
Journal:  J Med Genet       Date:  2005-11-18       Impact factor: 6.318

7.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Authors:  Aude Servais; Véronique Frémeaux-Bacchi; Moglie Lequintrec; Rémi Salomon; Jacques Blouin; Bertrand Knebelmann; Jean-Pierre Grünfeld; Philippe Lesavre; Laure-Hélène Noël; Fadi Fakhouri
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

8.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

9.  Prognostic factors in children with membranoproliferative glomerulonephritis type I.

Authors:  Silvestre García-de la Puente; Iraida Luz Orozco-Loza; Samuel Zaltzman-Girshevich; Beatriz de Leon Bojorge
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.